(Total Views: 272)
Posted On: 08/23/2021 10:55:52 AM
Post# of 56
$LXRX News Article - Lexicon's Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials https://marketwirenews.com/news-releases/lexi...35504.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼